// App-Quantinova.ai

PB1174 : Eptacog beta for resolution of bleeding episodes in patients with hemophilia A or B with inhibitors: Efficacy and safety according to inhibitor titer

Researchers

Presenter

  • D. Hart

Principal Investigators

  • R. Sidonio

  • S. Ahuja

  • M. Carcao

  • Y. Dargaud

  • M. Escobar

  • C. Kessler

  • O. Khan

  • C. Leissinger

  • P. Maes

  • M. Mancuso

  • W. Miesbach

  • M. Simpson

  • M. Wang

  • H. Wang

  • A. Srivastava

Medical Centers

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

  • Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, United States

  • UNC Hemophilia and Thrombosis Center; University of NC at Chapel Hill, Chapel Hill, North Carolina, United States

  • Rainbow Babies and Children's Hospital, Cleveland, OH, USA, Cleveland, Ohio, United States

  • Hospital Universitario La Paz, Madrid, Spain

  • Division of Haematology/Oncology, Department of Paediatrics and Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • GEMMAT, Groupe d'Etude Multidisciplinaire en Maladies Thrombotiques, Lyon, France4 Service de Médecine Intensive Réanimation, Hôpital Edouard Herriot, Lyon, France ; Unité d'Hémostase Clinique Hôpital Cardiologique Louis Pradel, Lyon, France ; UR4609 Hémostase & Thrombose, Université Claude Bernard Lyon 1, Lyon, LYON, Rhone-Alpes, France

  • University of Texas Health Science Center at Houston - Medical School, Houston, Texas, United States

  • Georgetown University School of Medicine, Washington, Dist. of Columbia, United States

  • University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

  • Tulane University, New Orleans, LA, United States

  • Antwerp University Hospital, Edegem, Belgium

  • IRCCS Humanitas Research Hospital, Milan, Lombardia, Italy

  • Unidad de Investigación Medica de Trombosis, Hemostasia y Aterogénesis. Instituto Mexicano del Seguro Social, Ciudad de Mexico, Distrito Federal, Mexico

  • Rush University Medical Center, Chicago, Illinois, United States

  • University of Colorado Hemophilia & Thrombosis Center, Aurora, United States

  • HEMA Biologics, Louisville, Kentucky, United States

  • NHLBI, Framingham, Massachusetts, United States

  • Christian Medical College, Vellore, India, Vellore, Tamil Nadu, India

Locations

  • United Kingdom

  • United States

  • Spain

  • Canada

  • France

  • Belgium

  • Italy

  • Mexico

  • Germany

  • India

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Cancer antigen 15-3

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02020369

Sponsors

  • N/A

Result

  • N/A